Complete Filing Data
Liminatus Pharma, Inc. reported Net Income Loss of -$10.21 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Liminatus Pharma, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income * | -$10.2M | -$3.5M |
| Operating Income Loss | -$3.0M | -$3.3M |
| Operating Expenses | $3.0M | $3.3M |
| Nonoperating Income Expense | -$7.2M | -$216.4K |
| Interest Expense Nonoperating | $215.9K | $338.9K |
| General And Administrative Expense | $3.0M | $644.6K |
| Research And Development Expense | $2.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$1.8M | $113.3K | -$327.5K | -$601.4K | -$961.2K | -$1.8M |
| Operating Income Loss | -$701.2K | -$1.1M | -$255.00 | -$543.1K | -$909.2K | -$247.00 |
| Operating Expenses | $701.2K | $1.1M | $543.1K | $909.2K | ||
| Nonoperating Income Expense | -$1.1M | $1.2M | -$58.2K | -$52.0K | ||
| Interest Expense Nonoperating | $19.1K | $62.3K | $92.7K | $77.2K | ||
| General And Administrative Expense | $701.2K | $1.1M | $186.1K | $195.1K | ||
| Research And Development Expense | $357.1K | $714.1K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | -$9.8M | -$19.3M | -$15.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $337.7K | $56.3K | $434.4K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $281.3K | -$378.1K | |
| Retained Earnings Accumulated Deficit | -$38.9M | -$28.7M | |
| Liabilities | $10.3M | $24.7M | |
| Property Plant And Equipment Net | $12.2K | $941.00 | |
| Prepaid Expense And Other Assets Current | $162.9K | $155.5K | |
| Liabilities And Stockholders Equity | $512.8K | $5.4M | |
| Assets Noncurrent | $12.2K | $127.2K | |
| Assets Current | $500.6K | $5.3M | |
| Assets | $512.8K | $5.4M | |
| Accrued Interest Current | $203.9K | $955.1K | |
| Accounts Payable And Accrued Liabilities Current | $582.2K | $1.5M | |
| Other Receivable After Allowance For Credit Loss Noncurrent | $126.3K | ||
| Deferred Costs Current | $0.00 | $1.4M | |
| Notes And Loans Receivable Net Current | $3.7M | ||
| Common Stock Value | $2.7K | $1.8K | |
| Common Stock Share Outstanding | $27.1M | $17.5M | |
| Repayments Of Short Term Debt | $1.3M | ||
| Liabilities Current | $10.3M | $24.7M | |
| Accrued Maintenance Fee Current | $360.0K | ||
| Equity Settlement Deferred Underwriting Fees Effect Of Change In Fair Value | -$196.0K | ||
| Deferred Transaction Costs In Accounts Payable | $561.4K | ||
| Gain Loss On Issuance Of Common Stock For Warrants | -$1.7M | ||
| Forgiveness Of Unrelated Vendor Payable | $2.1M | ||
| Deferred Underwriting Fees Payable In Cash Current | $500.0K | ||
| Liabilities Assumed1 | $10.7M | ||
| Debt Conversion Original Debt Amount1 | $14.8M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | -$1.6M | -$8.8M | -$19.7M | -$19.1M | -$18.5M | -$17.5M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $724.5K | $1.3M | $47.0K | $34.1K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $0.00 | $0.00 | ||||||
| Retained Earnings Accumulated Deficit | -$30.7M | -$28.9M | -$1.1K | |||||
| Liabilities | $3.0M | $10.7M | $1.1K | |||||
| Property Plant And Equipment Net | $12.8K | $198.00 | ||||||
| Prepaid Expense And Other Assets Current | $478.9K | $444.1K | ||||||
| Liabilities And Stockholders Equity | $1.3M | $1.9M | ||||||
| Assets Noncurrent | $139.0K | $126.5K | ||||||
| Assets Current | $1.2M | $1.8M | ||||||
| Assets | $1.3M | $1.9M | ||||||
| Accrued Interest Current | $184.9K | $165.8K | ||||||
| Accounts Payable And Accrued Liabilities Current | $559.2K | $431.9K | ||||||
| Other Receivable After Allowance For Credit Loss Noncurrent | $126.3K | $126.3K | ||||||
| Deferred Costs Current | ||||||||
| Notes And Loans Receivable Net Current | ||||||||
| Common Stock Value | $2.7K | $2.6K | $0.00 | |||||
| Common Stock Share Outstanding | $17.5M | $17.5M | $100.00 | |||||
| Repayments Of Short Term Debt | ||||||||
| Liabilities Current | $2.9M | $10.5M | ||||||
| Accrued Maintenance Fee Current | ||||||||
| Equity Settlement Deferred Underwriting Fees Effect Of Change In Fair Value | $560.0K | -$756.0K | ||||||
| Deferred Transaction Costs In Accounts Payable | ||||||||
| Gain Loss On Issuance Of Common Stock For Warrants | -$1.7M | |||||||
| Forgiveness Of Unrelated Vendor Payable | $2.1M | |||||||
| Deferred Underwriting Fees Payable In Cash Current | $500.0K | $500.0K | ||||||
| Liabilities Assumed1 | ||||||||
| Debt Conversion Original Debt Amount1 | ||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $0.00 | $0.00 | $0.00 | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$10.0M | -$1.5M |
| Proceeds From Short Term Debt | $4.3M | $3.9M |
| Payments To Acquire Loans Receivable | $775.0K | $2.9M |
| Net Cash Provided By Used In Investing Activities | -$788.1K | -$2.9M |
| Net Cash Provided By Used In Financing Activities | $11.0M | $3.9M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$324.6K | $133.3K |
| Increase Decrease In Accrued Interest To Related Party Current | -$215.9K | -$338.9K |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$4.0M | -$10.7K |
| Increase Decrease In Due To Related Parties Current | -$62.5K | |
| Increase Decrease In Due To Research And Development Partner Current | -$1.5M | |
| Increase Decrease In Accrued Maintenance Fees Current | -$360.0K | |
| Increase Decrease In Due From Related Parties Current | $3.4M | |
| Proceeds From Issuance Of Private Placement | $10.6M | |
| Payments Of Merger Related Costs Financing Activities | $2.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Cash Provided By Used In Operating Activities | $0.00 | $0.00 |
| Proceeds From Short Term Debt | ||
| Payments To Acquire Loans Receivable | ||
| Net Cash Provided By Used In Investing Activities | ||
| Net Cash Provided By Used In Financing Activities | ||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | ||
| Increase Decrease In Accrued Interest To Related Party Current | ||
| Increase Decrease In Accounts Payable And Accrued Liabilities | ||
| Increase Decrease In Due To Related Parties Current | ||
| Increase Decrease In Due To Research And Development Partner Current | ||
| Increase Decrease In Accrued Maintenance Fees Current | ||
| Increase Decrease In Due From Related Parties Current | ||
| Proceeds From Issuance Of Private Placement | ||
| Payments Of Merger Related Costs Financing Activities |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 23.8M | 17.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 23.8M | 17.5M |
| Earnings Per Share Diluted | $-0.43 | $-0.20 |
| Earnings Per Share Basic | $-0.43 | $-0.20 |
| Common Stock Shares Authorized | 500.0M | 500.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 1.0M | 1.0M |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Common Stock Shares Issued | 27.1M | 17.5M |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 |
| Preferred Stock Shares Issued | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 27.0M | 23.3M | 100.00 | 17.5M | 17.5M | 100.00 |
| Weighted Average Number Of Diluted Shares Outstanding | 27.0M | 23.3M | 100.00 | 17.5M | 17.5M | 100.00 |
| Earnings Per Share Diluted | $-0.07 | $0.00 | $-2.55 | $-0.03 | $-0.05 | $-2.47 |
| Earnings Per Share Basic | $-0.07 | $0.00 | $-2.55 | $-0.03 | $-0.05 | $-2.47 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 1.0K | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Authorized | 1.0M | 1.0M | ||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | ||||
| Common Stock Shares Issued | 27.1M | 26.0M | 100.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Investment Income Interest | $76.6K | $122.5K |
| Additional Paid In Capital | $29.1M | $9.3M |
| Short Term Borrowings | $1.4M | $20.0M |
| Fair Value Adjustment Of Warrants | -$54.3K | $0.00 |
| Warrants And Rights Outstanding | $29.2K | |
| Stock Issued Or Issuable To Underwriters Upon Consummation Of Business Combination | $7.0M | |
| Stock Issued During Period Value New Issues | $15.0M | |
| Stock Issued During Period Value Business Combination | $190.4K | |
| Stock Issued1 | $690.00 | |
| Noncash Conversion Of Amount Borrowed For Pipe Funds | $3.4M | |
| Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction | $1.5M | |
| Loans Settled | $4.4M | |
| Depreciation | $1.8K | |
| Adjustments To Additional Paid In Capital Settlement Of Loans | $4.4M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Investment Income Interest | $24.4K | $34.5K | $25.2K | ||
| Additional Paid In Capital | $29.1M | $20.1M | $10.00 | ||
| Short Term Borrowings | $1.4M | $1.4M | |||
| Fair Value Adjustment Of Warrants | -$76.9K | $116.9K | $0.00 | $0.00 | |
| Warrants And Rights Outstanding | $123.6K | $200.5K | |||
| Stock Issued Or Issuable To Underwriters Upon Consummation Of Business Combination | |||||
| Stock Issued During Period Value New Issues | $15.0M | ||||
| Stock Issued During Period Value Business Combination | $190.4K | ||||
| Stock Issued1 | |||||
| Noncash Conversion Of Amount Borrowed For Pipe Funds | |||||
| Merger Transaction Costs Incurred In Noncash Or Partial Noncash Transaction | |||||
| Loans Settled | |||||
| Depreciation | |||||
| Adjustments To Additional Paid In Capital Settlement Of Loans | $4.4M |
Most recent annual filing with the SEC: March 31, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.